Skip to Main Content

An official website of the United States government

Explore the Early Phase Prevention Trials
Access to Data and Biospecimens
View 0 Studies Requested

Phase Ib Biomarker Trial of Naproxen in patients at risk for DNA Mismatch Repair Deficient Colorectal Cancer

Enrollment Statistics

Actual Registration: 86

  • 80 people randomized
    • 25 in Arm I: Naproxen 220 mg
    • 27 in Arm II: Naproxen 440 mg
    • 28 in Arm III: Placebo
  • Six participants were not randomized; 5 participants did not meet all the screening requirements and 1 participant dropped due to target enrollment criteria limit met. (6 of 86 registered)